Downtown San Francisco

San Francisco — Amongst all the chaos and frenetic activity that abounds big Pharma at JPM each year, I always look forward to hearing what the smaller biotechs are up to on days 3 and 4, as well as seeing how far some of them have progressed since our previous update on their pipeline agents.

In this latest update, there are definitely some companies we have been following longitudinally who are either poised for future success and growth… or due for a correction if the promising science doesn’t pan out as expected in the clinic.

Indeed one of those companies has already hit success and disappointment in the last two months alone, such is the roller coaster that is oncology R&D.

Please note that this is a rolling blog, which means that numerous updates are added throughout the day as new information becomes available.

To learn more from our oncology coverage and get a heads up on our latest commentary JPM annual meeting, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

Posted by